These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

164 related items for PubMed ID: 2389954

  • 1. [Prevention of peritoneal recurrence by combined intra-peritoneal and intra-tumoral injections of OK-432].
    Baba H, Tsujitani S, Korenaga D, Kakeji Y, Haraguchi M, Konoe S, Maehara Y, Sugimachi K.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 2):1596-9. PubMed ID: 2389954
    [Abstract] [Full Text] [Related]

  • 2. [Effect of combined use of radiation and twice intratumor administration of OK-432 at one week intervals against a murine fibrosarcoma (NFSA)].
    Mukai M, Ando K, Koike S.
    Gan To Kagaku Ryoho; 1988 Apr; 15(4 Pt 1):631-5. PubMed ID: 3355184
    [Abstract] [Full Text] [Related]

  • 3. Synergistic therapeutic effect of combination therapy with OK-432 and interferon-alpha or -gamma on Meth-A ascites tumor in BALB/c mice.
    Mizushima Y, Morikage T, Hirata H, Sato M, Sakamoto K, Yano S.
    J Biol Response Mod; 1988 Aug; 7(4):371-83. PubMed ID: 3139841
    [Abstract] [Full Text] [Related]

  • 4. [Combined effect of the topical administration of OK-432 with radiation on the C3H mouse fibrosarcoma (NFSa)--TCD50 and the mechanism of action].
    Mukai M, Ando K, Koike S, Nagao K, Isono K.
    Gan To Kagaku Ryoho; 1986 Dec; 13(12):3432-5. PubMed ID: 3789754
    [Abstract] [Full Text] [Related]

  • 5. [Combined effects of cis-DDP and OK-432 on ascitic mastocytoma in mice: optimal period for the administration of OK-432].
    Komatsu K, Nakamura W.
    C R Seances Soc Biol Fil; 1986 Dec; 180(1):117-20. PubMed ID: 2943364
    [Abstract] [Full Text] [Related]

  • 6. [Combination therapy of local administration of OK-432 and radiation on a murine fibrosarcoma (NFSa)--combination effect and histological examination].
    Mukai M, Ando K, Koike S, Ishikawa T, Ryu M, Nagashima T, Nagao K, Isono K.
    Gan To Kagaku Ryoho; 1986 Mar; 13(3 Pt 1):556-62. PubMed ID: 3954378
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic effect of OK-432 induced endogenous TNF on tumor bearing mice and cancer patients.
    Watanabe N, Niitsu Y, Yamauchi N, Neda H, Sone H, Urushizaki I, Yamamoto A, Nagamuta M, Sugawara Y.
    Immunopharmacol Immunotoxicol; 1988 Mar; 10(1):53-65. PubMed ID: 3361071
    [Abstract] [Full Text] [Related]

  • 8. Intraperitoneal administration of the biological response modifier OK-432 and peritoneal recurrence following gastrectomy.
    Tsujitani S, Abe Y, Korenaga D, Saitoh A, Watanabe A, Sugimachi K.
    Hepatogastroenterology; 1990 Oct; 37(5):498-502. PubMed ID: 2253926
    [Abstract] [Full Text] [Related]

  • 9. Antitumor activity of orally administered streptococcal preparation, OK-432 on murine solid tumors and its absorption from the gut.
    Nio Y, Shiraishi T, Tsuchitani T, Tobe T, Sugawara Y, Saito M, Kamiyama H.
    In Vivo; 1989 Oct; 3(5):307-13. PubMed ID: 2519870
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. [Oral administration of streptococcal preparation "OK 432"--the 4th report: augmentation of in vitro anti-tumor immune responses of mice with transplanted cecal tumor].
    Tsuchitani T, Kodama H, Tobe T, Nio Y, Kan N, Inamoto T.
    Nihon Gan Chiryo Gakkai Shi; 1984 Oct 20; 19(9):2179-87. PubMed ID: 6530585
    [No Abstract] [Full Text] [Related]

  • 15. [Intraoperative and postoperative intra-peritoneal administration of peptide PIII inhibits peritoneal metastasis of gastric cancer].
    Bai FH, Yang L, Ji Q, Zhang YQ, Liu ZX, Wang ZZ, Yan L, Wang JB, Jin HF, Li TT.
    Zhonghua Yi Xue Za Zhi; 2006 Dec 12; 86(46):3260-3. PubMed ID: 17313805
    [Abstract] [Full Text] [Related]

  • 16. [Prevention of peritoneal carcinomatosis recurrence with a prostaglandin synthesis inhibitor, indomethacin].
    Narisawa T, Takahashi M, Masuda T, Nagasawa O, Koyama H.
    Gan To Kagaku Ryoho; 1987 Aug 12; 14(8):2496-501. PubMed ID: 3476022
    [Abstract] [Full Text] [Related]

  • 17. Effect of OK-432 on the lymphnode metastasis of MCA-sarcoma cell lines: a new therapeutic approach.
    Inoh A, Kodama Y, Yokoro K.
    Hiroshima J Med Sci; 1989 Dec 12; 38(4):213-9. PubMed ID: 2637250
    [Abstract] [Full Text] [Related]

  • 18. [Differences in the immunostimulatory activity and antitumor therapeutic effect of OK-432 and N-CWS].
    Mizushima Y, Iwata M, Sato M, Hirata H, Takashima A, Yano S.
    Gan To Kagaku Ryoho; 1986 Jul 12; 13(7):2404-10. PubMed ID: 3729493
    [Abstract] [Full Text] [Related]

  • 19. [Immunobiological studies of interferon-alpha A/D in comparison with a streptococcal preparation, OK-432].
    Mizushima Y, Hirata H, Sakamoto K, Sato M, Morikage T, Maruyama M, Sasaki K, Yano S.
    Gan To Kagaku Ryoho; 1987 Sep 12; 14(9):2710-5. PubMed ID: 3631971
    [Abstract] [Full Text] [Related]

  • 20. [Clinical investigation of intratumoral OK-432 administration].
    Shimada K, Tabuse K, Kono N, Katsumi M, Yamamoto H, Yamamoto Y, Endo A.
    Gan To Kagaku Ryoho; 1983 Aug 12; 10(8):1844-9. PubMed ID: 6882008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.